Will the Requirement by the US FDA to Simultaneously Co-Develop Companion Diagnostics (CDx) Delay the Approval of Receptor Tyrosine Kinase Inhibitors for RTK-Rearranged (ROS1-, RET-, AXL-, PDGFR-α-, NTRK1-) Non-Small Cell Lung Cancer Globally?

The discovery of anaplastic lymphoma kinase (ALK) rearrangement in non-small cell lung cancer (NSCLC) in 2007 and the approval of crizotinib for the treatment of advanced ALK-rearranged NSCLC in 2011 represents a landmark in the development of targeted oncology therapy. The approval of crizotinib wa...

Descripción completa

Detalles Bibliográficos
Autores principales: Ou, Sai-Hong Ignatius, Soo, Ross A., Kubo, Akihito, Kawaguchi, Tomoya, Ahn, Myung-Ju
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2014
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978317/
https://www.ncbi.nlm.nih.gov/pubmed/24744988
http://dx.doi.org/10.3389/fonc.2014.00058

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978317/
https://www.ncbi.nlm.nih.gov/pubmed/24744988
http://dx.doi.org/10.3389/fonc.2014.00058

Ejemplares similares